RSS 0393
Alternative Names: RSS-0393Latest Information Update: 08 Jul 2024
Price :
$50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
Most Recent Events
- 08 Jul 2024 Phase-I clinical trials in Psoriasis (Topical), prior to July 2024 (Jiangsu HengRui Medicine pipeline, July 2024) (NCT06308393)
- 18 Mar 2024 Jiangsu HengRui Medicine Co plans a phase I trial for Psoriasis (Topical), in March 2024 (NCT06308393)
- 18 Mar 2024 Preclinical trials in Psoriasis in China (Topical)